The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
Introduction. The use of doxorubicin in clinical practice has shown cumulative and dose-dependent toxic effects on cardiomyocytes, leading to an increase of mortality risk among patients with cancer and as a resulting to restrictions in the indications for its use.Text. A dangerous adverse reaction...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Russo |
| I whakaputaina: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-09-01
|
| Rangatū: | Разработка и регистрация лекарственных средств |
| Ngā marau: | |
| Urunga tuihono: | https://www.pharmjournal.ru/jour/article/view/1913 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|